IBRNvsXBI
iShares Neuroscience and Healthcare ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IBRN | XBI | |
|---|---|---|
| Expense ratio | 0.47% | 0.35% |
| Assets | $7864.21T | $11.4B |
| Net flow, 1 month | +$2M | +$351M |
| Net flow, 1 year | +$2M | +$1.8B |
| Return, YTD | +24.7% | +36.4% |
| Return, 1 year | +57.5% | +82.3% |
| Avg daily volume | 3K | 8.3M |
| Holdings | 54 | 135 |
| Listed | Aug 23, 2022 | Jan 30, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS